Adherence to antiretroviral therapy and treatment outcomes among conflict-affected and forcibly displaced populations: a systematic review. by Mendelsohn, Joshua B et al.
Mendelsohn, JB; Schilperoord, M; Spiegel, P; Ross, DA (2012) Ad-
herence to antiretroviral therapy and treatment outcomes among
conflict-affected and forcibly displaced populations: a systematic re-
view. Confl Health, 6 (1). p. 9. ISSN 1752-1505
Downloaded from: http://researchonline.lshtm.ac.uk/461947/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
REVIEW Open Access
Adherence to antiretroviral therapy and
treatment outcomes among conflict-affected and
forcibly displaced populations: a systematic
review
Joshua B Mendelsohn1*, Marian Schilperoord2, Paul Spiegel2 and David A Ross1
Abstract
Background: Optimal adherence to highly active antiretroviral therapy (HAART) is required to promote viral
suppression and to prevent disease progression and mortality. Forcibly displaced and conflict-affected populations
may face challenges succeeding on HAART. We performed a systematic review of the literature on adherence to
HAART and treatment outcomes in these groups, including refugees and internally-displaced persons (IDPs),
assessed the quality of the evidence and suggest a future research program.
Methods: Medline, Embase, and Global Health databases for 1995–2011 were searched using the Ovid platform. A
backward citation review of subsequent work that had cited the Ovid results was performed using the Web of
Science database. ReliefWeb and Médecins Sans Frontières (MSF) websites were searched for additional grey
literature.
Results and conclusion: We screened 297 records and identified 17 reports covering 15 quantitative and two
qualitative studies from 13 countries. Three-quarters (11/15) of the quantitative studies were retrospective studies
based on chart review; five studies included <100 clients. Adherence or treatment outcomes were reported in
resettled refugees, conflict-affected persons, internally-displaced persons (IDPs), and combinations of refugees, IDPs
and other foreign-born persons. The reviewed reports showed promise for conflict-affected and forcibly-displaced
populations; the range of optimal adherence prevalence reported was 87–99.5%. Treatment outcomes, measured
using virological, immunological and mortality estimates, were good in relation to non-affected groups. Given the
diversity of settings where forcibly-displaced and conflict-affected persons access ART, further studies on adherence
and treatment outcomes are needed to support scale-up and provide evidence-based justifications for inclusion of
these vulnerable groups in national treatment plans. Future studies and program evaluations should focus on
systematic monitoring of adherence and treatment interruptions by using facility-based pharmacy records,
understanding threats to optimal adherence and timely linkage to care throughout the displacement cycle, and
testing interventions designed to support adherence and treatment outcomes in these settings.
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Systematic review
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Introduction
It is widely accepted that for HIV-positive persons on
highly active antiretroviral therapy (HAART), high levels
of adherence to treatment regimens are essential for
promoting viral suppression and preventing drug resist-
ance. However, conflict-affected and forcibly displaced
populations such as refugees and internally-displaced
persons (IDPs) may face unique challenges in sustaining
good adherence to HAART and treatment outcomes
[1,2] while the potential for onward displacement pre-
sents a risk of pharmacy defaulting and treatment inter-
ruptions. An expectation of difficulty has clouded efforts
to provide HAART in these settings [3]. Forcibly dis-
placed populations consist mainly of refugees and IDPs,
however, definitions are often confused. According to
the Convention relating to the Status of Refugees, a refu-
gee is a person who:
. . .owing to well-founded fear of being persecuted for
reasons of race, religion, nationality, membership of a
particular social group or political opinion, is outside
the country of his nationality and is unable, or owing
to such fear, is unwilling to avail himself of the
protection of that country; or who, not having a
nationality and being outside the country of his former
habitual residence as a result of such events, is unable
or, owing to such fear, is unwilling to return to it [4].
The Inter-agency Standing Committee defines IDPs as:
. . .persons or groups of persons who have been forced
or obliged to flee or to leave their homes or places of
habitual residence, in particular as a result of or in
order to avoid the effects of armed conflict, situations
of generalized violence, violations of human rights or
natural or human-made disasters, and who have not
crossed an internationally recognized State border [5].
“Conflict-affected persons” are defined as persons resid-
ing in active or recent conflict zones or in a post-conflict
setting [6-8]. Around the world, some 1.5 billion people
live in countries affected by violent conflict, 14.7 million
people are internally displaced and 10.6 million are refu-
gees. Of refugees, 68% had been living in exile for ≥5
years in “protracted situations” [9,10]. The primary aim
of this review was to aggregate the available evidence on
adherence to HAART and treatment outcomes in refu-
gees, IDPs and conflict-affected persons, to assess the
quality of work undertaken so far and to suggest future
research needs.
Methods
A systematic review of the published literature was con-
ducted between 20 December 2011 and 20 January 2012
using a four step procedure. First, a search of the
Cochrane Database of Systematic Reviews yielded no
previous reviews. Second, we applied our search strategy
to the Medline, Embase, and Global Health databases
(including conference abstracts) using the Ovid plat-
form. The search strategy incorporated five themes:
“HIV”, “antiretroviral therapy”, “adherence”, “outcomes”,
and “forced migration.” Key words were combined with
medical subject headings (MeSH) to assess synonyms
applicable to each theme. The terms “refugee”, “intern-
ally-displaced”, “conflict-affected”, and “forced migra-
tion” were used to search the forced migration theme.
Table 1 presents a complete list of key words and MeSH
terms used. As adherence results are often reported in
papers where the primary aim is to report on clinical or
treatment outcomes, “disease” and “treatment” themes
were combined using the “OR” operator to create a
broad pool which could be cross-referenced with the
forced migration theme using the "AND" operator
(Additional file 1: Table S1). Searches were limited to
studies in English reported from 1995 onwards. Third, a
backwards citation search was performed using the Web
of Science “times cited” feature that identified all work
cited by any previously identified report in the health
science databases. Lastly, a check for sources that may
have been posted online but omitted from health science
databases was made by searching ReliefWeb and Méde-
cins Sans Frontières (MSF) websites and three experts
were consulted for additional sources. On the ReliefWeb
and MSF-UK websites, we used the expressions “anti-
retroviral and refugee” and “antiretroviral and IDP.” On
ReliefWeb, we searched under the “Analysis”, “Assess-
ment”, “Evaluation”, “Situation Report”, “UN document”
and “Other” content categories. Abstracts of papers
retrieved from all the above steps that were not editor-
ials, commentaries, case reports or had irrelevant titles
were subjected to a full-text review. Both qualitative and
quantitative studies of adult populations were included
in the final dataset if they presented relevant primary
data, secondary analyses on adherence to HAART or
treatment outcomes, and included adult conflict-affected
or forcibly displaced populations. We extracted and pre-
sented basic study information and data related to ad-
herence and treatment outcomes. PRISMA guidelines
were followed in the reporting of this review [11].
Results
Figure 1 presents the outcome of the search: out of 297
reports retrieved using the search strategy, 17 reports
conducted in 13 countries with 8,930 clients were
retained for this review. Table 1 summarises the data
extracted from selected reports. Three studies reported
results for IDPs only. Kiboneka and colleagues [12] con-
ducted a prospective cohort study to measure clinical
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Table 1 Descriptions of quantitative studies included in the systematic review
Location; study
period [Ref]
Study type Population
[comparison
group]
Time on
HAART
Relevant reported
HAART adherence
outcome
Relevant
reported
treatment
outcome
Adjusted analysis
(outcome; factors
associated with
outcome with
p<0.05)
Lacor Hospital,
Gulu District,
Uganda; June
2005-Jan 2008
[12]
Prospective
cohort study
by structured
questionnaire
IDPs, n=1625;
14% residing in
IDP camps,
86% residing in
outlying areas;
>14 years-old
Cumulative
patient-years
follow-up=1981
Composite of
pharmacy monitored
drug possession ratio,
pharmacy refill records,
and 3-day self-reported
recall by patients or
caregivers:
Mortality
incidence=3.48
(95% CI 2.66-4.31)
per 100 person-
years, log rank
p-value<0.01;
Lower all-cause
mortality:
-Sex, female vs.
male (HR=0.7
95% CI 0.55-0.91,
p=0.02)
[No comparison
group]
≥95% doses taken as
prescribed=92.2%
Median CD4
change
(IQR)= 0 (0-0)
-Baseline CD4
count, per 100
cell increase
(HR=0.14, 95%
CI 0.06-0.34,
p<0.001)
Lacor Hospital,
Gulu District,
Uganda;
Jan-Feb 2008
[13]
Cross-
sectional
survey by
semi-
structured
questionnaire
IDPs, n=200; 29%
residing in IDP
camps, 71%
residing in
outlying areas;
≥18 years-old
≤12
months=
33.0%
13-24 months=
29.5%
>24 months=
37.5%
Mean 4-day
self-reported
adherence recall,
≥95% doses
taken as
prescribed= 99.5%
NA <95%
adherence:
-First line vs.
second line
treatment
[OR=22.22, 95%
CI 1.48-333.33,
p=0.03]
[No comparison
group]
-Staff were
condemning,
yes vs. no
(OR=22.22,
95% CI
1.5-333.33,
p=0.02)
Nyanza
province,
Kenya;
Dec 2007-July
2008 [14]
Retrospective
cohort study
by review of
demographic
surveillance
data
IDPs, n=28
(proportion
on HAART
unknown); rural;
≥5 years-old
Not known NA 53% (28/53) HIV
mortality in IDPs
vs. 25% (235/936)
HIV mortality in
2008 DSS
residents, p<0.001
NA
[IDP HIV mortality
compared with
prior DSS residents]
Kinkala/
Mindouli,
Republic of
Congo;
May 2006-
Dec 2007 [15]
Retrospective
cohort study
by chart
review
Conflict-affected,
n=222; rural;
adults ≥15
years-old
Mean follow-up
time on
HAART=9
months
NA Probabilities
of survival
-(n=129) at
6 months=0.94
95% CI
0.89-0.96
NA
[No comparison
group]
-(n=70) at
12 months=0.89
95% CI 0.82-0.93
12 MSF
programs;
Oct 2003-
[2]
Retrospective
cohort study
by chart
review
Conflict-affected,
n=2572; rural; adults
≥15 years-old
[No comparison
group]
Median follow-
up time on
HAART=11.8
months
(IQR 3.9-22.7)
NA -Median
probability of
survival at
12 months 0.89,
95% CI 0.88-0.91
NA
-Proportion lost to
follow-up 0.11,
95% CI 0.09-0.12
-Median 6-month
CD4 gain=129
cells/mm3
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Table 1 Descriptions of quantitative studies included in the systematic review (Continued)
Location; study
period [Ref]
Study type Population
[comparison
group]
Time on
HAART
Relevant reported
HAART adherence
outcome
Relevant
reported
treatment
outcome
Adjusted analysis
(outcome; factors
associated with
outcome with
p<0.05)
MSF Project,
Bukavu,
Democratic
Republic of
the Congo;
May 2002-Jan
2006 [16]
Retrospective
cohort study
by chart
review
Conflict-affected,
n=494; urban and
outlying areas
[Compared with
18 low-income
setting cohorts in
Africa, Asia, and
South America
and 12 high-
income setting
cohorts in Europe
and North America]
Person-years
follow-up=235
>95% pills taken as
prescribed as of last
clinic visit, measured
by pill counts=99%
6-month median
CD4 gain (IQR):
163 (82-232)
12-month
mortality
(95% CI)=7.9%
(3.6-12.1)
NA
Equatorial
region
of southern
Sudan; July
2009-March
2010 [17]
Retrospective
cohort study
by chart
review
Refugees and IDPs,
n=159 (69% living in
refugee camps, 12%
internally-displaced
at time of HAART start);
rural; adults age-cut-off
not reported [No
comparison group]
64% on HAART
for ≥6 months
>95% adherence by
self-report over
past month=88%
(of those on HAART
for ≥6 months)
NA NA
Nazareth
House,
Johannesburg,
South Africa;
April 2004-
March 2007
[18]
Retrospective
cohort study
by chart
review
Foreigners, n=568
(% refugees or IDPs
unknown); urban;
age≥16 [Compared
with local citizens
(n=431) and persons
of unknown
citizenship (n=298)]
Median (IQR)
person-years
on HAART:
NA Viral failure (ART
cessation, patient
death, viral load
>1000 copies/mL,
any decrease in
CD4 from pre-ART
levels):
Viral failure (ART
cessation, patient
death, viral load
>1000 copies/mL,
any decrease in
CD4 from pre-ART
levels):
-Foreigners=0.5
(0.1-0.9)
-Local
citizens=0.6
(0.2-1.1)
-Foreigners=
24%
-Local citizens=
42%
-Citizenship status,
foreigner vs. local
citizen (OR=0.45,
95% CI 0.23-0.87,
p= 0.017)
-Unknown
citizenship=0.5
(0.2-1.1)
-Unknown=
53%
p-value
(foreigners
vs. local
citizens) = 0.001
-Opportunistic
infections, TB
before ART vs.
none (OR=2.5,
95% CI 1.4-4.5,
p=0.002)
Coptic Hope
Centre for
Infectious
Diseases,
Nairobi, Kenya;
December
2006-February
2007 [19]
Retrospective
cohort by
chart review
Local population,
n=2,534; Kenyan
residents; age ≥18
[Compared with
n=2,167 one year
earlier, before
post-election
violence]
Median
duration on
treatment (IQR)
19.5 months
(9.8-28.5)
Comparison
group was
“similar”
Proportion
interrupting
treatment
(visiting
pharmacy
≥48 hours
after ARTs
completed)
NA -Odds of TI during
PEV increased by
71% 95%CI 34
to 118]
-16.1% in
PEV group
-10.2% in
comparison
group
-During post-
election violence,
odds of TI
increased for
men (OR=1.37,
95%CI 1.07
to 1.76, p=0.01)
and clients
travelling
≥ 3 hours to
clinic (OR=1.86,
95% CI 1.28 to
2.71, p=0.001)
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Table 1 Descriptions of quantitative studies included in the systematic review (Continued)
Location; study
period [Ref]
Study type Population
[comparison
group]
Time on
HAART
Relevant reported
HAART adherence
outcome
Relevant
reported
treatment
outcome
Adjusted analysis
(outcome; factors
associated with
outcome with
p<0.05)
Miriam
Hospital,
Providence,
Rhode Island,
USA; 2000–
2006 [20]
Matched
case-control
study by
retrospective
chart review
Refugees, n=52
(29 started ART);
non-refugees,
n=52 (41 started ART);
urban [Controls
were non-refugees
matched on gender]
NR Adherence to
scheduled
appointments:
-Refugees=75%
-Non-refugees=
86%,
p=0.17
-Initiation of HAART:
Refugees=56%
-Non-refugees=79%
(OR=0.37, 95%
CI 0.13-0.92, p=0.03)
Not reported NA
Mangere
Refugee
Resettlement
Centre,
Auckland,
New Zealand;
June 1993-
June 2004
[21]
Retrospective
cohort study
by chart
review
Refugees from
Africa and Asia,
n=98 (n=60 started
HAART); urban
[No comparison
group]
NR NA Undetectable
viral load 1 year
after HAART
start= 61%
(36/59)
NA
Boston Medical
Centre, USA;
June 2000-
June
2001 [22]
Retrospective
cohort study
by chart
review
Refugees, n=34,
n=15 on HAART;
urban [No
comparison
group]
NR “Reported
adherence with
medications”=
87%
Undetectable
viral load
(not defined)=
87%
NA
Southern
Alberta, Canada;
Jan 2001-Jan
2007 [23]
Retrospective
cohort study
by chart
review
Sub-Saharan
African, n=126
(68% refugees);
Other foreign-born,
n=72 (14% refugees)
[Canadian-born,
n=455]
NR “Good adherence
within foreign-born
patients to HAART”
(data not shown)
80% viral
suppression
(no comparison
between groups
reported)
NA
Miriam Hospital,
Providence,
Rhode Island,
USA; 2000–
2006 [24]
Retrospective
cohort study
by chart
review
Pregnant, resettled
refugee women,
n=14; rural
[No comparison
group]
NR Lost to
follow-up=1/14
(7%)
Median viral
load at time of
pregnancy=3.36
log10 copies/mL
NA
Median viral load
at time of
delivery=1.88
log10 copies/mL
Great Lukole
camp,
Tanzania;
Oct 2002-
Sept 2004
[25]
Retrospective
cohort study
by chart
review
Women delivering
in camp, n=189
[No comparison
group]
NA Single dose nevirapine
uptake at labour=98%
(185/189) excluding
repatriated women and
62% (185/301) including
refusals and repatriations
NA NA
NA (not applicable)=outcome not applicable/analysis not done; NR (not reported)=data not reported.
IDP=internally-displaced person; OR=odds ratio; HR=hazard ratio; CI=confidence interval; IQR=inter-quartile range; HAART=highly active antiretroviral therapy;
ART=antiretroviral therapy; TB=tuberculosis; TI=treatment interruption.
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and immunological outcomes of HAART clients in Gulu
District, northern Uganda, the site of civil strife and con-
flict between the Ugandan government and the Lord’s
Resistance Army guerrilla group. Adherence was mea-
sured by combining pharmacy monitoring, pharmacy re-
fill records and patient self-report, and dichotomised at
the ≥95% level. Over a median follow-up time of 13.7
months for clients with complete adherence data
(n=1,521), 92.2% had ≥95% adherence. Among patients
with <95% adherence, 9.3% died compared with 1.2% of
patients with ≥95% adherence. In an adjusted analysis,
mortality was less likely among women (Hazard ratio,
HR=0.7, 95% confidence interval, 95%CI 0.55, 0.91;
p=0.02) and clients with >200 CD4 at treatment start
(HR=0.14, 95%CI 0.06, 0.34; p<0.001). A second cross-
sectional study of IDPs in Gulu District reported a high
(99.5%) mean self-reported four-day adherence to
HAART [13]. In this study, clients who were on first-
line therapy (Odds ratio, OR=22.22, 95%CI 1.53, 333.33;
p=0.02) or who reported that clinic staff were “con-
demning” (OR=22.22, 95%CI 1.53, 333.33; p=0.02) were
more likely to report non-adherence. A study of mortal-
ity among Kenyan IDPs in the post-election violence
period of 2007–2008 found increased mortality in HIV-
positive IDPs when compared with mortality during the
same period among HIV-positive residents captured in
the same Demographic Surveillance Survey catchment
area prior to the violence [14].
We identified six studies that reported on conflict-
affected, mixed refugee and IDP populations, or unspeci-
fied foreigners, including both refugees and asylum-seekers.
O’Brien and colleagues [2], reporting on a pooled analysis
of 12 MSF conflict and post-conflict HAART programs
(n=2,572), found a median probability of survival at 12
months of 0.89 (95%CI 0.88, 0.91). Two further MSF
studies of individual programs found good survival out-
comes. In a post-conflict program in the Republic of
Congo [15], the survival probability at 12 months was
0.89 (95%CI 0.82, 0.93). In a study from Bukavu, Demo-
cratic Republic of the Congo (DRC) during an active
conflict involving the central government, insurgents and
proxy armies from neighbouring states [16], optimal
HAART adherence (defined as missing less than 5% of
pills between clinic visits) measured by pill counts was
attained by 99% of participants, although the limitations
of this method in this setting were not specified. The
conflict setting had higher 12-month mortality (7.9%,
95%CI 3.6, 12.1) than comparison settings, but the six-
month median CD4 cell gain of 163 cells/mm3 compared
favourably with cohorts from a resource-limited setting
(106 cells/mm3) and a resource-rich setting (103 cells/
mm3). In the Equatorial province of Sudan, Salami and
Figure 1 Study selection flowchart.
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colleagues [17] found that 88% of refugees and IDPs on
HAART for ≥6 months self-reported ≥95% adherence. A
South African study comparing self-identified foreigners
with local citizens reported that foreigners were less
than half as likely (OR=0.45, 95%CI 0.23, 0.87; p=
0.017) to have suffered viral failure, defined as ART
cessation, any decrease in CD4 from pre-ART levels, a
viral load of >1000 copies/mL, or death [18]. In a Kenyan
study that used a pre-post design to investigate treat-
ment interruptions (TI) (defined as the proportion vis-
iting pharmacy ≥48 hours after ARTs completed),
16.1% experienced a TI during post-election violence
compared with 10.2% in the comparison period [19].
For clients who overlapped between the two periods,
the odds of TI were elevated by 71% during post-
election violence (95%CI 34, 118, p<0.001]. Men
(OR=1.37, 95%CI 1.07, 1.76; p=0.01) and clients travel-
ling more than three hours to the clinic (OR=1.86,
95%CI 1.28, 2.71; p=0.001) also were more likely to ex-
perience a TI.
Four studies were conducted among HIV-positive
refugees in high income settings. An HIV-positive refu-
gee cohort in Rhode Island, USA, had lower odds of
initiating HAART when compared with non-refugees
(OR=0.37, 95%CI 0.13, 0.92; p=0.03) and had a lower
attendance at scheduled appointments relative to non-
refugees (75% v. 86%, p=0.17) [20]. In a New Zealand-
based refugee cohort on HAART, 61% had an
undetectable HIV viral load after one year of treatment
[21]; a US study reported undetectable viral load in 87%
of refugees receiving HAART [22]. In a Canadian study,
80% of a cohort consisting of native-born clients, refu-
gees and other immigrants from Sub-Saharan African
and elsewhere were virologically suppressed [23]. In this
study, the rate of progression to new opportunistic
infections or AIDS-defining events was higher among
the former group (0.1 v. 0.06 events/1000 patient-days)
while the mortality rate restricted to HIV-related deaths
was higher among the latter group (0.8 v. 1.2 deaths/
1000 patient-months).
Two studies dealt exclusively with pregnant mothers
taking ART for prevention of mother-to-child transmis-
sion (PMTCT). The first study, conducted among a
resettled group of refugees on HAART during pregnancy
in Rhode Island, USA, reported a reduction in median
viral load at the time of delivery [24]. A study conducted
in a Tanzanian refugee camp reported a 98% (185/189)
uptake of nevirapine at the time of delivery, but women
who initially refused the medication or who were repa-
triated to their native countries prior to delivery were
not included [25].
Two additional qualitative studies were also eligible for
review. One study conducted in Teso, northern Uganda
[26], identified security while attending clinics, food
security, distance to health centres and access to health
providers as the main concerns of clients and health
workers in relation to HAART adherence. Respondents
noted that food insecurity and single daily meals made
multiple daily dosing a challenge during famines and
floods. A second study from northern Uganda [27]
reported on the impact of social networks on long-term
provision of antiretrovirals. This study reported that
community-based volunteers and health workers were
effective in supporting adherence and the formation of
social support groups, while social networks assisted in
overcoming challenges that were independently related
to displacement and stigma. Notably, but perhaps unsur-
prisingly, the study identified inadequate planning in the
return phase of the forced displacement cycle as present-
ing significant challenges in patient monitoring, missed
appointments, and loss to follow-up. Finally, in a qualita-
tive sub-study (counted as a quantitative study for the
purposes of Figure 1), Pyne-Mercier and colleagues [19]
reported that 6/ 13 interviewed clients had been
attacked by mobs or had their homes or businesses van-
dalised during post-election violence in Kenya. Lack of
transport and inflated transport costs were identified as
barriers to accessing treatment, while personal commit-
ment and support from family and clinic social workers
facilitated access to treatment.
Discussion and conclusions
This review revealed a limited number of studies on ad-
herence to HAART and treatment outcomes, however
the outcomes observed in the reviewed studies showed
promise for conflict-affected and forcibly displaced
populations. The range of optimal adherence prevalence
of 87–99.5% compared favourably with other settings. A
meta-analysis of 84 observational studies reported a 62%
average reporting rate of ≥90% adherence [28]. A second
meta-analysis comparing resource-limited and resource-
rich settings [29] reported that 55% of North American
populations and 77% of sub-Saharan African populations
achieved adequate adherence. Important factors nega-
tively affecting adherence in sub-Saharan Africa included
non-disclosure of HIV status to a loved one for fear of
stigma, alcohol abuse, and difficulty following complex
drug regimens. In a separate review of barriers to adher-
ence, pooled results from ten quantitative studies in
developing countries identified financial constraints
(52%, 95%CI 16, 88) and forgetfulness (36%, 95%CI 19,
55) as major barriers [30]. A review of African studies
[31] reported that 68-99% of patients were ≥95% adher-
ent but found no studies documenting the use of formal
adherence intervention programs. The present review
identified one study [13] that compared conflict-affected
or forcibly displaced groups to a local host community
or that assessed potential barriers to, and facilitators of
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adherence and/or treatment outcomes. Garang and col-
leagues found no significant differences in adherence be-
tween IDPs and non-IDPs (99.6% v. 99.5%) and reported
that being on first-line treatment and clients’ perceived
condemnation by medical staff reduced the odds of op-
timal adherence. Barriers to adherence in this study
included depression after losing a child, forgetfulness,
travelling, and not refilling medications on schedule.
We located one study that specifically studied treat-
ment interruptions [19]. Understanding the prevalence
and consequences of treatment interruptions is highly
relevant for conflict-affected and forcibly displaced
groups given their previous displacement history and the
potential for onwards travel including resettlement or
repatriation after initiation of therapy. Studies in other
population groups that investigated interruptions as
therapeutic alternatives to continuous therapy such as
intentional treatment holidays and unintentional inter-
ruptions have found harmful results. Initial concerns
about long-term safety and reports of a lack of improved
virological response in trials of structured interruptions
[32,33] were confirmed by the Strategies for Manage-
ment of Antiretroviral Therapy (SMART) study, which
found that CD4-guided episodic therapy increases the
risk of opportunistic disease or death in relation to con-
tinuous treatment [34]. A review of unstructured TIs
found an increased risk of opportunistic infections, viro-
logical failure, drug resistance, poor immunological re-
covery and death [35]. Future studies on forcibly
displaced and conflict-affected groups should facilitate
the monitoring of TIs by combining data from facility-
based pharmacy records and mobile phone follow-up
contact with clients that confirm TIs when clients fail to
report for routine pharmacy refill appointments.
The studies included in this review were conducted in
a variety of contexts including camps, rural, and urban
areas in low-income settings and urban areas in high-
income settings. Although the studies did not describe
the specific features of the clinics where HAART was
delivered, these were likely variable in relation to the
type of institutional provider, which ranged from
publicly-run hospitals to non-governmental organisa-
tions, and their respective resource levels. Given the im-
portance of context for outcomes, the variation in
settings may have affected the reported findings and
merit further study. The majority (14/15) of the reviewed
quantitative studies were facility-based. When clients
present at new treatment facilities, HIV testing and
counselling is routinely administered where indicated
and HAART is initiated according to national guidelines,
regardless of treatment history. With the exception of
the MSF studies where no previous HIV testing had
taken place, the question of whether treatment start at
the study facility was equivalent to treatment initiation,
or if treatment had been started elsewhere prior to on-
wards displacement and arrival at the study facility, was
not verifiable. Establishing the date and location of
HAART initiation is challenging in any setting where
medical records are not routinely shared and client recall
of their complete treatment history may be compromised.
Where possible, investigations that attempt to address
these shortcomings will be useful for estimating the effect
of forced displacement on adherence and treatment out-
comes and for correctly interpreting findings. Moreover,
the categorisation of displaced persons presents additional
challenges; definitions may affect the network of provi-
ders, the availability of particular services, and the extent
of co-payments (if any). For example, in non-refugee
camp settings a lack of documentation or xenophobic
attitudes may present obstacles to accessing key services
including HIV counselling, testing, and ART. To facilitate
generalisability to similar settings and population groups,
future studies should be mindful of these categorizations
and their impact on outcomes.
There were some limitations to this review. Although
we searched health databases and grey literature, it is
possible that relevant studies were omitted; we limited
our search to reports published in English. To minimise
this risk of exclusion, we used a backwards citation
search and expert consultation. Most identified studies
used a single adherence indicator, which suggested a
possibility of measurement bias. Although there is
no widely accepted standard for measuring adherence,
self-report and pharmacy refills are the most commonly
used instruments in resource-limited settings [36,37].
Triangulation is one way to enhance confidence in
measurement validity, especially in challenging multi-
linguistic or complex emergency settings. Guidelines
developed by an International Association of Physicians
in AIDS Care Panel recommended routine use of both
self-reports and pharmacy refill measures [38]. Where
possible, multiple adherence measurements should be
used, especially when more objective measures such as
medication event monitoring systems (MEMS) are not
feasible and biomarkers are not available from medical
records or are too difficult or expensive to collect.
The geographic breadth of quantitative studies was
limited: 53% (8/15) of the studies were conducted with
asylum-based refugees and IDPs in African settings.
Notably, only one study dealt with documented refugees
in low-income settings [17]. The limited number of
studies, small sample sizes (five included <100 clients),
lack of comparison groups and varied outcomes and
indicators suggest that estimates may have suffered from
selection and response biases. We did not undertake a
meta-analysis due to the substantial differences between
client groups, methods, and outcomes across studies.
Despite these difficulties, the reviewed studies were
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designed around local circumstances: samples were ei-
ther limited by the absolute number of clients with avail-
able records to review, the study was facility-based and
only had access to a limited pool of clients, or an evalu-
ation of adherence and treatment outcomes was not the
primary aim. Response bias was likely to have been less
of a concern in the study by Kiboneka and colleagues
[12], where a comprehensive adherence assessment of all
HIV-positive clients attending one hospital was under-
taken. However, the risk that the small number of stud-
ies available for review were conducted in settings more
suitable for research, for example where data existed in a
form particularly conducive to chart reviews, may have
biased the findings towards better outcomes.
If HAART is to be scaled-up in conflict-affected and
forcibly displaced clients, studies designed to assess
adherence and treatment outcomes will be critical for
optimising treatment outcomes and preventing drug re-
sistance associated with widespread distribution of medi-
cations, the use of less tolerated regimens, restricted
virological monitoring, and the potential for inconsistent
drug supply [39]. The World Health Organisation’s
(WHO) public health strategy for mitigating drug resist-
ance recommends providing highly effective first-line
regimens, prescribing previously unused drug classes
when switching after first-line treatment failure, reserv-
ing the drugs that are least likely to provoke resistance
for patients whose first-line treatments are no longer ef-
fective, and administering regimens that encourage ad-
herence [40]. For forcibly-displaced and conflict-affected
clients, these principles raise important questions. What
is the most effective first-line regimen for these settings
[41]? When clients are displaced and have a poor know-
ledge of their treatment history, which HAART regimen
should be used? Are HIV-positive individuals who were
started on HAART prior to displacement identified
quickly in the host setting, linked to care in a timely
manner, and succeeding on treatment? Are best practices
correctly implemented prior to voluntary repatriation or
resettlement to a third country? Which factors, regimen-
related or otherwise, encourage good adherence? Recent
intervention studies in resource-limited settings have
shown that counselling services and mobile phone-based
reminders helped to maintain adherence and viral sup-
pression [42,43]. Although trials have not been con-
ducted among conflict-affected and forcibly-displaced
populations, a useful basis for an intervention consisting
of a 7-step support package and tailored to the needs of
migrants, refugees, and asylum-seekers was delivered by
MSF in Musina. This report, published after our review
period, found that 92% (95%CI 75.2, 97) of clients were
virologically suppressed (<400 copies/mL) at 12 months
after receiving this intervention, which included a
patient-held record (“health passport”), an alternative
treatment site road map, anticipation of travel at regular
clinic visits, a safe travel pack (including buffer stock of
ARVs, a washout regimen, and a transfer letter), migrant-
adapted treatment counselling, a questionnaire for
returning patients and migrant-adapted monitoring of
retention in care [44].
In summary, the limited evidence from the small series
of studies available for this review suggests that HAART
adherence and treatment outcomes among conflict-
affected and forcibly displaced adults may be as good as
outcomes attained in unaffected population groups. Fu-
ture research should consider stronger study designs
that address TIs throughout the displacement cycle,
more geographic variation, the use of a systematic, rep-
licable, and triangulated approach to adherence monitor-
ing, and the design and testing of interventions to
improve adherence and treatment outcomes. Given that
refugees in asylum countries tend to remain for an aver-
age of 17 years [45], there is a strong national interest
and humanitarian rationale for ensuring universal access
to HIV treatment and care, promoting optimal outcomes
among all vulnerable groups and developing a consensus
approach to achieving these goals [46]. For effective
HAART scale-up in conflict-affected and forcibly dis-
placed clients, assessing adherence and treatment out-
comes will be critical for promoting viral suppression,
preventing drug resistance and reducing onward
transmission.
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